ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - inflúensu, manna - bóluefni - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - skal læknir hafa blöðrum bólgur veira (álag indiana) með eyðingu umslagið glýkóprótein, komi með zaire ebolavirus (álag kikwit 1995) yfirborðið glýkóprótein - blæðandi hiti, ebóla - bóluefni - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. notkun ervebo ætti að vera í samræmi við opinbera tillögur.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - einstofna mótefni - Áður ómeðhöndlað langvarandi eitilfrumuhvítblæði (cll): arzerra ásamt klórambúcíl eða bendamustine er ætlað fyrir sjúklinga með cll sem hafa ekki fengið áður en meðferð og hver ert ekki hæf til flúdarabín byggir meðferð. fallið cll: arzerra er ætlað ásamt flúdarabín og cýklófosfamíði fyrir meðferð fullorðinn sjúklinga með fallið cll. svarar cll: arzerra er ætlað fyrir meðferð cll í sjúklingum sem svarar til flúdarabín og alemtuzumab.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - hvítblæði, hairy cell - Æxlishemjandi lyf - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - mígreni kvilla - verkjalyf - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, meðferð, sýnt fram á að hjá - háþrýstingur - hjarta og æðakerfi - rasitrio er ætlað til meðferð við háþrýstingi eins og stað meðferð í fullorðinn sjúklingar sem blóðþrýstingur er nægilega stjórn á sambland af aliskiren, meðferð og sýnt fram á að hjá gefið samtímis á sama skammti eins og í samsetning.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, meðferð - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - rasilamlo er ætlað til meðhöndlunar á nauðsynlegum háþrýstingi hjá fullorðnum sjúklingum, þar sem blóðþrýstingur er ekki nægilega stjórnað með aliskireni eða amlodipini sem er notað eitt sér.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

amgen europe bv - sotorasib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.